UK committee grills GSK and Roche on data disclosure policies
This article was originally published in SRA
Executive Summary
More indications that the focus of the debate over wider clinical trial data disclosure has – at least in Europe – shifted away from commercial confidentiality to the protection of personal data came from testimony by pharmaceutical industry executives at this week's UK evidence session at the House of Commons' science and technology committee1.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.